Hepatitis Research Review, Issue 29

In this Issue:

Entecavir is an option for childhood HBV
DAA therapy: first-line for HCV-MCS?
DEPDC5 variants confer susceptibility to severe fibrosis
Cost-effectiveness of DAA regimens in treatment-naïve HCV
Exploring how HBV may inhibit miR-122 activity
Daclatasvir + simeprevir ± ribavirin in GT1 HCV
OBV/PTV/r and DSV for GT1b HCV with cirrhosis
Cleaved c-FLIP mediates TNF-α antiviral effect against HBV
Successful HCV treatment with DAAs in real-world setting
Do not avoid statins in HCV with compensated cirrhosis

Please login below to download this issue (PDF)

Subscribe